We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
95 hedge funds and large institutions have $766M invested in Dianthus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
11.81% more ownership
Funds ownership: 106.86% → 118.67% (+12%)
4% more funds holding
Funds holding: 91 → 95 (+4)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
11% less capital invested
Capital invested by funds: $859M → $766M (-$93M)
31% less call options, than puts
Call options by funds: $9K | Put options by funds: $13K
Holders
95
Holders Change
+4
Holders Change %
+4.4%
% of All Funds
1.25%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
41
Reduced
24
Closed
12
Calls
$9K
Puts
$13K
Net Calls
-$4K
Net Calls Change
-$4K
Top Buyers
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$38.6M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$18.3M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$17.5M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$9.35M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.33M |
